Clinical experience with ioversol 320 in cranial computed tomographic scanning.
Sixty patients referred to the Mallinckrodt Institute of Radiology at Washington University School of Medicine, St. Louis, participated in an open-label, noncomparative study of the safety, tolerance, and efficacy of the contrast agent ioversol 320 in cerebral computed tomographic (CCT) scanning. None of the patients experienced any drug-related, clinically significant changes in vital signs or any serious adverse reactions; nor did they report experiencing pain when the agent was injected intravenously. In addition, the radiographic quality of the scans was rated as excellent or good for patients who had enhanceable brain lesions. All CCT scans were considered diagnostic. In this series, ioversol 320 proved to be safe, well tolerated, and effective for use in CCT scanning.
Sartor
K
K
Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri 63110.
Gado
M H
MH
Hodges
F J
FJ
D000293:Adolescent; D000328:Adult; D000368:Aged; D001831:Body Temperature / Q000187:drug effects; D001927:Brain Diseases / Q000000981:diagnostic imaging* / Q000503:physiopathology; D002986:Clinical Trials as Topic; D003287:Contrast Media; D004361:Drug Tolerance; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007463:Iodobenzoates; D008297:Male; D008875:Middle Aged; D010147:Pain Measurement; D014057:Tomography, X-Ray Computed; D014283:Triiodobenzoic Acids / Q000633:toxicity
D003287:Contrast Media; D007463:Iodobenzoates; D014283:Triiodobenzoic Acids; C054871:ioversol